Clinical Trial Update: Effectiveness and Safety Trial of a New Ischemic Stroke Treatment Within 24 Hours From Stroke Onset (NEST-2) [Phase 3]

View source ↗

Summary

The Phase 3 NEST-2 trial evaluating a new ischemic stroke treatment administered within 24 hours of onset has completed, reporting its effectiveness and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• NEST-2 Investigational Therapy

Snippet

Sponsor: PhotoThera, Inc | Conditions: Ischemic Stroke | Phase 3 | Status: COMPLETED